Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="center"><em>SPA Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr</em></p> <p align="center"><em>Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023 </em></p> <p align="center"><em>Sath Shukla Became President and CEO, Effective August 1</em></p> <p align="center"><em>Conference call and webcast...